HC Wainwright reissued their buy rating on shares of CytoDyn (OTCMKTS:CYDY) in a research report released on Wednesday morning.

Separately, ValuEngine upgraded shares of CytoDyn from a strong sell rating to a sell rating in a research note on Thursday, September 7th.

Shares of CytoDyn (OTCMKTS:CYDY) opened at $0.59 on Wednesday. CytoDyn has a 12 month low of $0.46 and a 12 month high of $0.84.

CytoDyn (OTCMKTS:CYDY) last posted its quarterly earnings data on Tuesday, October 10th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). sell-side analysts forecast that CytoDyn will post -0.19 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/12/03/cytodyn-cydy-earns-buy-rating-from-hc-wainwright.html.

About CytoDyn

CytoDyn Inc is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company’s lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells.

Receive News & Stock Ratings for CytoDyn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn Inc. and related stocks with our FREE daily email newsletter.